The clinical significance of MSI2 in NSCLC is strongly supported by genomic and proteomic database analyses in NSCLC tissues and stroma, which showed the association of MSI2 expression with the disease as well as with its progression and poor prognosis in NSCLC patients. This evidence concerns the gene MSI2 and non-small cell lung carcinoma.